MRNA Trading Analysis - 11/20/2026 03:27 PM — TRU-SENTIMENT

MRNA (Moderna Inc. Common Stock) at $195.22. True Sentiment Balanced, delta 40-60 call 54% / put 46%, call $8,712,950 vs put $7,497,220. RSI 42.8.

TRU-SENTIMENT · DeltaNeutral

MRNA Trading Analysis - 11/20/2026 03:27 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

MRNA (Moderna Inc. Common Stock) at $195.22. True Sentiment Balanced, delta 40-60 call 54% / put 46%, call $8,712,950 vs put $7,497,220. RSI 42.8.

Symbol
MRNA
Price
$195.22
Article bias (separate from True Sentiment)
neutral
Conviction
low
Published
2026-11-20 15:27:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

Options flow sentiment is Balanced. Call dollar volume 8,712,950.00 vs put 7,497,220.00; call pct 53.70, put pct 46.30. Total 16,210,170.00. Pure directional conviction shows slight call tilt but balanced per methodology. Near-term expectations: no clear bias; aligns with neutral technicals. Divergence: mild call dominance yet price below SMA 50 — slight disagreement.

Call Volume: 8,712,950.00 (53.70%) Put Volume: 7,497,220.00 (46.30%) Total: 16,210,170.00

Note: Options flow shows balanced sentiment with 6.8% filter ratio of true directional contracts.

Key Statistics: MRNA

$194.84 -2.58%
52-Week Range
$22.28 - $280.80
Market Cap
$77.79B
P/E (TTM)
22.20
PEG Ratio
N/A
Beta
0.07
Next Earnings
N/A
Avg Volume
$14.04M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)22.20
EPS (trailing 12 mo)$-7.04
Market cap$77.79B
Shares outstanding399.2M

Dividend

Dividend yield0.00%

Risk & range

Beta0.07
52-week low$22.28
52-week high$280.80
Historical volatility103.3%

Ownership & trading

Institutional ownership66.1%
Average daily volume11.3M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

Recent general-knowledge headlines and context for Moderna (MRNA) that may frame the current data environment:

  • Moderna reported updated COVID-19 and flu combination vaccine trial progress, with regulatory submissions anticipated in early 2027.
  • The company faced pricing pressure concerns after competitor mRNA product approvals expanded in international markets.
  • Institutional investors trimmed positions in mid-cap biotech during Q4 2026 amid sector rotation into defensives.
  • No confirmed near-term earnings date in provided data; fiscal year end listed as 2025-12-01 with next major options expiration 2026-12-18.
  • Headlines suggest cautious sentiment; this aligns with embedded balanced options flow and neutral technical bias rather than strong directional conviction.

Fundamental Analysis

Based strictly on embedded FUNDAMENTALS data for MRNA:

  • Trailing P/E is 22.20; however trailing EPS is -7.04, indicating the company is not currently profitable on a trailing basis.
  • PEG ratio, forward P/E, forward EPS, profit margins, revenue growth, ROE, and debt/equity are all null — not available in data.
  • Market cap is 77,787,341,858.00 with shares outstanding of 399,236,000.00 and dividend yield of 0.00.
  • Beta is 0.07 (very low systemic risk per data), 52-week high 280.80 and low 22.28; historical volatility is 103.31%.
  • Institutional ownership is 66.11%; average volume 11,300,000.00.
  • Analyst consensus and target mean price are null — no embedded analyst view.
  • Fundamentals show negative earnings with incomplete margin data; this diverges from prior price strength (close 270.35 on 2026-11-09) but aligns with recent pullback and balanced sentiment.

Current Market Position

Current price per indicators is 200.00 (as of 2026-11-19 close). Minute bars show 2026-11-19 open 196.03, high 205.22, low 189.98, close 200.00. Last 2026-11-20 bars show recovery from 191.98 to 195.22 by 14:55. Recent daily history shows decline from 270.35 (2026-11-09) to 197.74 (2026-11-18) then 200.00 (2026-11-19). Intraday 2026-11-20 momentum improved late session with close 195.22 above low 189.98 prior day.

Support
189.98
Resistance
205.22
20-day SMA
225.16
50-day SMA
206.68
Bollinger Lower
182.35

Technical Analysis

Technical Indicators

RSI (14)
42.84
MACD
0.95
Signal
0.76
Histogram
0.19
SMA 5
208.40
SMA 20
225.16
SMA 50
206.68
ATR 14
18.11

SMA 5 (208.40) below SMA 20 (225.16) and SMA 50 (206.68) reflects bearish short-term alignment; price 200.00 below all three. RSI 42.84 shows weak momentum, not oversold. MACD positive histogram 0.19 implies minor bullish crossover. Bollinger middle 225.16, upper 267.97, lower 182.35 — price near lower third. 30-day range high 280.80, low 179.53; price near lower boundary. Format adherence: all values two decimals.

True Sentiment Analysis (Delta 40-60 Options)

Options flow sentiment is Balanced. Call dollar volume 8,712,950.00 vs put 7,497,220.00; call pct 53.70, put pct 46.30. Total 16,210,170.00. Pure directional conviction shows slight call tilt but balanced per methodology. Near-term expectations: no clear bias; aligns with neutral technicals. Divergence: mild call dominance yet price below SMA 50 — slight disagreement.

Call Volume: 8,712,950.00 (53.70%) Put Volume: 7,497,220.00 (46.30%) Total: 16,210,170.00

Note: Options flow shows balanced sentiment with 6.8% filter ratio of true directional contracts.

Key Price Levels (Observational Only)

Support (daily low)
189.98
Resistance (daily high)
205.22
Bollinger Lower
182.35
SMA 50
206.68
SMA 20
225.16

Interactive charts load with JavaScript. This text is the crawlable summary.